NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 4 August 2022

**Location:** via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Lindsay Smith (Vice Chair) Present for all items
3. James Avery Present for all items
4. Martin Bradley Present for all items
5. Professor Rachel Elliott Present for all items
6. Dr Robert Hodgson Present for all items
7. Dr Bernard Khoo Present for all items
8. Ivan Koychev Present for all items
9. Dr Soo Fon Lim Present for all items
10. Dr Guy Makin Present for all items
11. Philip Mallender Present for all items
12. Giles Monnickendam Present for all items
13. Dr Malcolm Oswald Present for all items
14. Professor Chris Parker Present for items 1 – 4.2.2
15. Dr Rebecca Payne Present for all items
16. Carole Pitkeathley Present for all items
17. Dr Raju Reddy Present for all items
18. Professor John Watkins Present for all items

NICE staff present

Ross Dent, Associate Director Present for items 1 – 5.2.2

Jasdeep Hayre, Associate Director Present for items 6 – 6.2.2

Louise Jafferally, Project Manager Present for items 1 – 5.1.3 & 6 – 6.2.2

Kate Moore, Project Manager Present for items 1 – 4.1.3 & 5 – 6.2.2

Carl Prescott, Heath Technology Assessment Adviser Present for items 1 – 5.2.2

Alexandra Filby, Heath Technology Assessment Adviser Present for items 1 – 5.2.2

Caron Jones, Heath Technology Assessment Adviser Present for items 1 – 5.2.2

Sally Doss, Heath Technology Assessment Adviser Present for items 6 – 6.2.2

Fatima Chunara, Heath Technology Assessment Analyst Present for items 1 – 5.2.2

Anuja Chatterjee, Heath Technology Assessment Analyst Present for items 1 – 5.2.2

Haider Shamsi, Heath Technology Assessment Analyst Present for items 6 – 6.2.2

Maroulla Whiteley, Business Analyst, RIA Present for all items

Stephen Norton, Technical Analyst, Managed Access Present for items 1 – 5.2.2

Neha Jiandani, Technical Analyst, Commercial Risk Assessment Present for items 1 – 5.2.2

Korin Knight, Senior Medical Editor Present for items 1 – 4.2.2

Helen Barnett, Senior Medical Editor Present for items 5 – 5.2.2

Hayley Garnett, Senior Medical Editor Present for items 6 – 6.2.2

James Baker, Media Relations Executive, Press Office Present for items 1 – 5.2.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Present for items 1 – 4.1.3 & 5 – 5.1.3

Lyn Davies, Coordinator, MIP Present for items 1 – 4.1.3 & 6 – 6.1.3

Emma Gordon, Coordinator, MIP Present for items 5 – 5.1.3

Catherine Pank, Assistant Project Manager, COT Present for items 6 – 6.2.2

Sandra Robinson, Assistant Project Manager, Corporate Office Present for items 5 – 5.1.3 & 6 – 6.1.3

Laura Kelly, Administrator, COT Present for all items

Iain Cannell, Administrator, TA Present for items 1 – 4.2.2

Mohammed Towhasir, Administrator, TA Present for items 5 – 5.2.2

Leah Kelly, Administrator, TA Present for items 6 - 6.2.2

NICE Observers present

Seamus Kent, Senior Adviser, Data & Analytics Team, NICE Present for items 1 – 5.2.2

Dr Radha Todd, NICE observer Present for items 1 – 5.2.2

External assessment group representatives present

Nigel Armstrong, KSR Present for items 1 – 4.1.3 & 5 – 5.1.3

Willem Witlox, KSR Present for items 1 – 4.1.3

Bram Ramaekers, KSR Present for items 5 – 5.1.3

Matt Stevenson, ScHARR Present for items 6 – 6.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drugs Fund Lead, NHS England Present for items 1 – 5.2.2

Dr Alistair Greystoke, Senior Lecturer & Honorary Consultant in Medical Oncology, Clinical expert nominated by British Thoracic Oncology Group, Present for items 1 – 4.1.3

Deborah Littell, Patient expert nominated by EGFR Positive UK Present for items 1 – 4.1.3

Angela Terry, Patient expert nominated by EGFR Positive UK Present for items 1 – 4.1.3 & 5 – 5.1.3

Steve MacDonald, Patient expert nominated by EGFR Positive UK Present for items 5 – 5.1.3

Professor Sanjay Popat, Consultant Medical Oncologist, Clinical expert nominated by BTOG & Takeda UK, Present for items 5 – 5.1.3

Dr Yvonne Summers, Consultant Medical Oncologist, Clinical expert nominated by Takeda UK, Present for items 5 – 5.1.3

Professor Detlef Bockenhauer, Consultant Paediatric Nephrologist, Clinical expert nominated by Renal Association, Present for items 6 – 6.1.3

Dr Jan Dudley, Consultant Paediatric Nephrologist, Clinical expert nominated by Renal Association, Present for items 6 – 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from committee members.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 7 July 2022

### Appraisal of amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy [ID3836]

* 1. Part 1 – Open session
		1. The chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Janssen.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Dr Matthew Bradley declared financial interests as he holds shares in AstraZeneca, a potential comparator manufacturer. It was agreed that his declaration would prevent Dr Bradley from participating in discussions on this appraisal.
* Prior to the meeting, Dr Ivan Koychev declared an indirect financial interest as he has a collaboration with JnJ in an unrelated area (Alzheimer's disease) as part of which they are investigating blood biomarkers for Alzheimer's disease. Dr Ivan Koychev also further declared an indirect financial interest, due to having a past collaboration with Roche as part of which digital technologies were developed for the detection of cognitive impairment in ageing adults, which has now concluded. It was agreed that this would not prevent Dr Koychev from participating in this discussion.
* Dr Alistair Greystroke declared a direct financial interest as he has received consultancy and speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche, and Takeda for treatments in NSCLC. Dr Greystroke also declared direct non-financial interests, as he is clinical lead for cancer for the NEY Genomic Laboratory Hub responsible for genomic testing in his region, and a member of the Genomics Test Evaluation Working Group (Cancer). It was agreed that this would not prevent Dr Greystroke from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Bernard Khoo, Malcolm Oswald and Fatima Chunara.
	1. Part 2 - Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10729>

1. Appraisal of mobocertinib for treating EGFR Exon 20 insertion-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3984]
	1. Part 1 – Open session
		1. The vice chair, Dr Lindsay Smith, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Takeda UK.
		2. The vice chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Dr Matthew Bradley declared financial interests as he holds shares in AstraZeneca, a potential comparator manufacturer. It was agreed that his declaration would prevent Dr Bradley from participating in discussions on this appraisal.
* Prior to the meeting, Dr Ivan Koychev declared an indirect financial interest as he has a collaboration with JnJ in an unrelated area (Alzheimer's disease) as part of which they are investigating blood biomarkers for Alzheimer's disease. Dr Ivan Koychev also further declared an indirect financial interest, due to having a past collaboration with Roche as part of which digital technologies were developed for the detection of cognitive impairment in ageing adults, which has now concluded. It was agreed that this would not prevent Dr Koychev from participating in this discussion.
* Professor Sanjay Popat declared a direct financial interest, as he has received consultancy & honoraria fees from Amgen, AstraZeneca, Janssen, Takeda, Pfizer, and various other companies. Prior to the meeting, Professor Popat also declared various indirect non-financial interests, as an advisor for ALK Positive UK, Lung Cancer Europe, Ruth Strauss Foundation (non-reimbursed), committee chair of BTOG Steering and Council Member for ETOP-IBSCG Partners Foundation (non-reimbursed) and for sitting on the board of directors Mesothelioma Applied Research Foundation (non-reimbursed.) It was agreed that these declarations would not prevent Professor Popat from providing expert advice to the committee
* Dr Yvonne Summers declared a direct financial interest, as she has participated in paid advisory board and educational activities for the nominating company. It was agreed that this declaration would not prevent Dr Summers from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Giles Monnickendam, Professor John Watkins, and Carole Pitkeathley.
	1. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10881>

1. Appraisal of slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis [ID3787]
	1. Part 1 – Open session
		1. The chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Advicenne.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Dr Matthew Bradley declared financial interests as he is an employee of GSK, a stated comparator manufacturer. It was agreed that his declaration would prevent Dr Bradley from participating in discussions on this appraisal.
* Professor Detlef Bockenhauer declared direct and indirect financial interests as he has received speaking honoraria and other fees from Advicenne, and the Renal Association received sponsorship (£500) from Advicenne for the BAPN winter meeting. Professor Bockenhauer has a special interest in this condition and has led a recent European project to develop treatment. It was agreed that these declarations would not prevent Professor Bockenhaur from providing expert advice to the committee.
* Prior to the meeting, Dr Jan Dudley declared indirect interests as The Renal Association received sponsorship (£500) from Advicenne for the BAPN winter meeting. It was agreed that this declaration would not prevent Dr Dudley from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the chair.
	1. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10753>

1. Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 7 September 2022 and will start promptly at 09:30.